© 2003 BMJ Publishing Group Ltd & British Thoracic Society
Airwaves
| The first 150 words of the full text of this article appear below. |
There is now considerable evidence that inhaled steroids reduce exacerbation frequency in patients with more severe COPD, although evidence that they affect disease progression has been lacking. In this issue of Thorax Rand Sutherland and colleagues report a meta-analysis of eight large studies of 2 or more years which evaluated the longer term effects of inhaled steroids. The meta-analysis concluded that inhaled steroid treatment slows the rate of decline in FEV1 and that the effect is greater with higher dose regimes. This meta-analysis is further discussed by Burge and Lewis in an accompanying editorial in which they explain why the results of the present study differ from a previously published meta-analysis of long term inhaled steroid treatment. Burge and Lewis also point out that future studies should now pay attention to the optimal inhaled steroid dose, the stage of disease severity for commencing treatment, and the effects of combinations with
This article has been cited by other articles:
-
Hahn, D L, Burge, P S, Lewis, S A
(2004). Ethics of placebo controlled studies of inhaled steroids for COPD * Authors' reply. Thorax
59: 539-540
[Full Text] -
Duerden, M G
(2004). Do inhaled corticosteroids slow FEV1 decline in COPD after all?. Thorax
59: 538-539
[Full Text]
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
